{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 75 of 92', 'CR845-CLIN3103', '8.9', 'Additional Analyses', '8.9.1', 'Inflammatory Biomarkers', 'The observed value and the change in inflammatory biomarkers (eg, IL-6, IL-8, and', 'granulocyte macrophage-colony stimulating factor) from pre-dose to the end of the', 'Double-blind Treatment Period (Week 12) will be presented by treatment group.', 'Univariate and multivariate analyses of the change in inflammatory biomarkers will be', 'described in an analysis plan, separate from the study SAP.', '8.9.2', 'Missed Dialysis Visits and Incidence of Infection', 'The number and percentage of patients who missed 1 or more dialysis visits during the', 'Double-blind Treatment Period, and the total number of missed dialyses visits will be', 'tabulated overall and by treatment group.', 'Incidence of infections based on adverse events, hospitalizations, and/or use of antibiotics', \"for treatment of infection related to uremic pruritus will be analyzed using Fisher's Exact\", 'Test.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 76 of 92', 'CR845-CLIN3103', '9.0', 'Quality Control and Quality Assurance', '9.1', 'Study Monitoring Plan', 'Monitoring and auditing procedures that comply with current Good Clinical Practice', '(GCP) guidelines will be followed, including remote and onsite review of the eCRFs via', 'an electronic data capture system for completeness and clarity, source document', 'verification, evaluation of protocol adherence, appropriate documentation of informed', 'consent procedures, safety reporting, study drug storage, and dispensation. The study', 'will be monitored by the Sponsor or its designee (contract research organization).', 'Monitoring will be performed by a representative of the Sponsor or its designee (site', 'monitor) who will review patient enrollment, eCRFs, source documents, drug', 'accountability records, and reporting and recording of adverse events. The site monitor', 'will ensure that the investigation is conducted according to protocol design and', 'regulatory requirements by frequent site visits and communications (letter, telephone, and', 'facsimile).', 'The site monitor(s) will follow written standard operating procedures as agreed with the', 'contract research organization and the Sponsor. The site monitor(s) will verify that the', 'clinical study is conducted and data are generated, documented (recorded), and reported', 'in compliance with the protocol, GCP, and the applicable regulatory requirements.', 'Monitoring reports will be submitted to the Sponsor in a timely fashion as per details', 'described in a clinical monitoring plan for this study.', 'Name and contact information for monitors will be included in the ISF.', '9.2', 'Audits and Inspections', 'The investigational site will maintain appropriate medical and research records for this', 'study, in compliance with ICH-GCP, regulatory, and institutional requirements for the', 'protection of confidentiality of participants. The Investigator must allow access to', 'authorized persons or institutions to complete data source verification. Source data are', 'all information, original records of clinical findings, observations, or other activities in a', 'clinical study necessary for the reconstruction and evaluation of the study. Examples of', 'these original documents and data records include, but are not limited to, hospital records,', \"clinical and office charts, laboratory notes, memoranda, participants' diaries or evaluation\", 'checklists, pharmacy dispensing records, recorded data from automated instruments,', 'copies or transcriptions certified after verification as being accurate and complete,', 'microfiches, photographic negatives, microfilm or magnetic media, x-rays, and', 'participant files and records kept at the pharmacy, laboratories, or medical-technical', 'departments involved in the clinical study, as applicable.', 'The investigational site will provide access to all study-related sites, source', 'data/documents, and reports for the purpose of monitoring and auditing by the Sponsor', 'and inspection by local and regulatory authorities.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 77 of 92', 'CR845-CLIN3103', '9.3', 'Data Collection, Validation, and Analysis', 'A data management vendor will ensure that quality assurance procedures are', 'implemented, beginning with the data entry system and generation of data quality control', 'checks that will be run on the database.', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}